Skip to content
DataLookout
Menu

NCT03519464

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 359 versions: 7 with changes below, 43 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed
    • Primary completion date changed from estimate of Dec 31, 2026 to Mar 6, 2026
  2. New version filed on ClinicalTrials.gov
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 100 to confirmed 54
    v342
  4. Notable Primary and study completion dates: Dec 31, 2025 to Dec 31, 2026v341
  5. Minor Secondary endpoints: details revised at 2 of 2 entriesv336
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Primary and study completion dates: Feb 28, 2024 to Dec 31, 2025v335
  2. Notable Primary and study completion dates: Feb 28, 2023 to Feb 28, 2024v331
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of patients with ICL who become seropositive to at least 1 homologous HPV vaccine genotype at 1 month after completion of the vaccination schedule.
Timeframe: 1 month (+ 1 month) after vaccination #3.

Secondary (2)

Humoral responses, expressed as geometric mean titer (GMT), will be compared between patients with ICL and healthy subjects, within the subgroup of subjects who seroconvert for any specific homologous HPV genotype.
Number of adverse events (AEs) and serious adverse events (SAEs) following administration of 9-valent HPV recombinant vaccine.

Arms and interventions

ICL and Healthy VolunteersOther

Biological/Vaccine

Biologicals: Gardasil 9

Sites

1 site in 1 country

  • National Institutes of Health Clinical CenterBethesda, Maryland, United States